genedrive plc (LON:GDR – Get Free Report) passed below its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of GBX 1.23 and traded as low as GBX 1.03. genedrive shares last traded at GBX 1.08, with a volume of 227,983 shares trading hands.
genedrive Stock Performance
The company has a debt-to-equity ratio of -120.48, a quick ratio of 5.52 and a current ratio of 0.99. The business has a fifty day simple moving average of GBX 1.23 and a 200 day simple moving average of GBX 1.16. The company has a market cap of £17.26 million, a P/E ratio of -1.36 and a beta of 0.97.
Insider Buying and Selling at genedrive
In other news, insider Gino Miele purchased 700,000 shares of the company’s stock in a transaction that occurred on Friday, August 28th. The shares were acquired at an average cost of GBX 1 per share, with a total value of £7,000. Company insiders own 28.09% of the company’s stock.
genedrive Company Profile
genedrive plc is a pharmacogenetic testing company developing and commercialising a low cost, rapid, versatile and simple to use point of need pharmacogenetic platform for the diagnosis of genetic variants. This helps clinicians to quickly access key genetic information that will aid them make the right choices over the right medicine or dosage to use for an effective treatment, particularly important in time-critical emergency care healthcare paradigms. Based in the UK, the Company is at the forefront of Point of Care pharmacogenetic testing in emergency healthcare.
Featured Articles
- Five stocks we like better than genedrive
- Is Texas Instruments Setting Up for Its Next Big Breakout?
- Pegasystems’ Q3 Miss Exposed the Problem Standing Between AI and Cash Flow
- Lam Research’s Earnings Beat Wasn’t the Real Story—Its 2027 Outlook Was
- Tesla’s Flying-Car Hype Hits an Earnings Reality Check
Receive News & Ratings for genedrive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for genedrive and related companies with MarketBeat.com's FREE daily email newsletter.
